batirtze-areitio Batirtze Areitio Batirtze has over 5 years of experience in the biopharma and biotech industries. She joined ApexOnco in 2025 after working as an analyst at OncologyPipeline. She is a graduate of the University of Navarra, where she earned a degree in biochemistry. The EU door to China-based approvals is open 23 September 2024 Akeso’s CD47 heads for phase 3 23 September 2024 Dato sees double survival trouble 23 September 2024 Achilles follows Instil’s lead 19 September 2024 Merck’s patritumab-dxd case strengthens 18 September 2024 ESMO 2024 – Bristol abandonment overshadows Immatics 17 September 2024 ESMO 2024 – Amgen’s PRMT5 still looks lacklustre 17 September 2024 ESMO 2024 – Bristol bucks the degrader trend 16 September 2024 Load More